Kane Biotech Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNBIF research report →
About the company
Kane Biotech Inc. is a biotechnology firm specializing in the research, development, and global commercialization of innovative technologies and products focused on preventing and eradicating microbial biofilms. The company's diverse product lineup includes pet dental care solutions under the StrixNB and bluestem brands, as well as DispersinB for treating wounds in both animals and humans.
- CEO
- Robert Huizinga
- IPO
- 2007
- Employees
- 20
- HQ
- Winnipeg, MB, CA
Price Chart
- Market Cap
- $4.00M
- P/E
- -2.38
- P/S
- 105.02
- P/B
- -3.85
- EV/EBITDA
- -3.07
- Div Yield
- 0.00%
- Gross Margin
- -390.49%
- Op Margin
- -4487.60%
- Net Margin
- -3785.93%
- ROE
- 277.77%
- ROIC
- -503.38%
- Revenue
- $427.52K · -79.45%
- Net Income
- $-2,719,021 · -144.59%
- EPS
- $-0.02 · 29.24%
- Op Income
- $-3,109,787.2
- FCF YoY
- 22.46%
- 52W High
- $0.04
- 52W Low
- $0.02
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 0.31
- Avg Volume
- 7.75K
Get TickerSpark's AI analysis on KNBIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our KNBIF coverage
Recent articles, reports, and earnings notes.
No research on KNBIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KNBIF report →Similar companies
Peers in the same neighborhood.